An interventional study of Polynucleotide and hyaluronic acid-based gel and Control in Periodontitis, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Periodontitis by University of Sao Paulo — 3 open to participants now, 4 under way, none of them phase 3. Periodontitis · University of Sao Paulo.
Among the 13 studies in Periodontitis by University of Sao Paulo, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 with no phase, and was the 9th registered.
1,242 studies on the registry are indexed under Periodontitis; 304 are open to participants now.
Browse Periodontitis studies →3 of the 13 studies in Periodontitis by University of Sao Paulo are open now, in 1 country. Recruiting first, the newest first:
University of Sao Paulo · Sites in Brazil
Ages 18–70
University of Sao Paulo · Sites in Brazil
Ages 18–70
By country, each count listing its studies:
Of the 163 Periodontitis studies recruiting now, 80 (49%) set no upper age limit and 62 (38%) stop at 75 or younger; 12 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 66 is above the median of 44 across 850 interventional studies indexed under Periodontitis.
Median enrollment 46 across the 12 interventional studies, 33 across the 1 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Periodontitis by University of Sao Paulo that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07463859University of Sao PauloEffects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabetes Mellitus | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Periodontitis by University of Sao Paulo, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Over the last 30 years, the prevalence of periodontitis (PE) has increased substantially, including among younger populations, highlighting the need to improve the management of this condition as a chronic disease and to develop techniques that favor its control and stability in the short and long term. After non-surgical periodontal therapy (NSPT), the first phase of PE treatment, residual periodontal pockets may persist, often associated with intraosseous defects, which compromise the tooth's prognosis and are associated with disease progression and increased treatment complexity. Surgical treatment of intrabony defects often results in the formation of long junctional epithelium, weakly attached to the root surface, since true regeneration of periodontal tissues is an unpredictable event and depends on complex biological processes. In recent decades, various biomaterials have been proposed as aids to open-flap debridement (OFD) in the surgical treatment of intrabony defects, with the aim of promoting periodontal regeneration, enhancing clinical results and favoring treatment prognosis. Recently, the combination of polynucleotides (PN) and hyaluronic acid (HA) has emerged as a promising auxiliary strategy to promote periodontal regeneration, due to its biological potential in stimulating cell growth and increasing cell viability. The aim of this controlled, randomized, parallel-group clinical study is to compare OFD alone with its association with xenogenous bone graft or xenogenous bone graft plus gel containing PN/HA in the surgical treatment of intrabony defects in patients with PE (stages III or IV, grades B or C). The patients will be randomly divided into three experimental groups (n=22): control (C), xenogeneic bone graft (XENO) and xenogeneic bone graft plus gel containing PN/HA (R-XENO). The patients will receive NSPT, and after eight weeks will undergo surgical procedures to treat the intrabony defects (baseline). Clinical, radiographic, tomographic and immunological periodontal parameters will be assessed at baseline and after 12 months. The wound healing index will be recorded 1, 2 and 6 weeks after the surgical procedure. Patient-centered outcomes will be assessed by means of a visual analog scale (VAS), applied two weeks after the surgical procedure, and oral health-related quality of life (OHRQoL) questionnaires, applied at the beginning of the study and after 6 and 12 months. At the start of the study and after 6 and 12 months, anthropometric data will be collected, blood pressure (BP) will be measured and questionnaires will be applied to survey socio-demographic and nutritional parameters. The data obtained will be statistically analyzed (p\<0.05).
This controlled, randomized, parallel-group clinical study aims to compare open-flap debridement alone with its association with xenogeneic bone graft or xenogeneic bone graft plus gel containing polynucleotides (PN) and hyaluronic acid (HA) in the surgical treatment of intrabony defects in patients with periodontitis (stages III or IV, grades B or C), based on clinical, immunologic, radiographic/tomographic parameters and patient-centered outcomes.
The sample size was calculated using the primary variable clinical attachment level (CAL), considering a mean difference of 1 mm between the experimental groups as the minimum value and a standard deviation of 0.91. Considering β = 80% and α = 5%, the required sample size was 18 patients for each experimental group, with each patient contributing a single defect. Considering a dropout of 20%, the number was increased to 22 patients per experimental group, making a total of 66 patients.
Patients who meet the inclusion criteria will be randomly assigned to one of three experimental groups (n=22) in a 1:1 allocation ratio: Group C (Control), including intrabony defects treated with open flap debridement alone; Group XENO, including open flap debridement associated with xenogeneic bone grafting; and Group R-XENO, including open flap debridement associated with xenogeneic bone grafting and a PN/HA-containing gel. Randomization will be performed using software, which will identify each participant by a numerical code. Group allocation will be carried out on the day of surgery by the study coordinator.
Surgical treatment: After local anesthesia using an infiltration or nerve block technique with a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) and 1:100,000 epinephrine (10 µg/mL), intrasulcular incisions will be made on the buccal and lingual/palatal aspects using a 15C surgical blade (Stainless Steel Surgical Blades, Swann-Morton®, Sheffield, England), extending one tooth mesially and one tooth distally to the tooth associated with the defect. A full-thickness flap will be carefully elevated on the buccal and lingual/palatal sides to expose 2 to 3 mm of the alveolar crest. Meticulous debridement of the defect will be performed, along with the removal of subgingival biofilm and calculus using ultrasonic combined with manual instruments, followed by irrigation with sterile saline solution. The defects will be filled as follows: with blood clot only in the group C; with xenogeneic bone graft (Geistlich Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) in the XENO group; and with xenogeneic bone graft (Geistlich Bio-Oss®) plus PN/HA-containing gel (REGENFAST®, Geistlich Pharma AG, Wolhusen, Switzerland) in the R-XENO group. Primary soft tissue closure was achieved by interrupted mattress suture technique with non-resorbable monofilament polyamide 5-0 sutures (Soft Blue®, Techsuture, Bauru, SP, Brazil).
Outcome assessment will be conducted at predefined time points. The primary outcome is clinical attachment level (CAL). Secondary outcomes include probing depth (PD); radiographic and tomographic measures of bone fill and defect resolution; quantitative analysis of biomarkers related to tissue neoformation (PDGF-BB, VEGF, BMP-2); early wound healing assessed by standardized indices; and patient-reported outcomes, including pain perception and oral health-related quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intrabony defects treated with open flap debridement alone
Other: Control
Intrabony defects treated with open flap debridement associated with xenogeneic bone grafting
Device: Xenogeneic bone graft
Intrabony defects treated with open flap debridement associated with polynucleotide and hyaluronic acid-based gel plus xenogeneic bone grafting
Device: Polynucleotide and hyaluronic acid-based gel
The polynucleotide and hyaluronic acid-based gel will be applied in combination with a xenogeneic bone graft to fill the intrabony defects.
Intrabony defects treated with open flap debridement alone
The xenogeneic bone graft will be applied to fill the intrabony defects.
Clinical Attachment Level (CAL)
Distance between the cemento-enamel junction and the bottom of the periodontal pocket/sulcus, in milimeters
Time frame: Baseline and 12 months
Probing depth (PD)
Distance between the gingival margin and the bottom of the periodontal pocket/sulcus, in milimeters
Time frame: Baseline and 12 months
Changes in the alveolar bone crest
Distance between the cemento-enamel junction and the alveolar crest in milimeters, assessed radiographically
Time frame: Baseline and 12 months
Radiographic defect depth
Distance between the alveolar crest and the defect base in milimeters, assessed radiographically
Time frame: Baseline and 12 months
Vertical bone loss
Distante between the cemento-enamel junction and the defect base in milimeters, assessed radiographically
Time frame: Baseline and 12 months
Tomographic vertical bone loss
Distance, in milimeters, between the cemento-enamel junction and the defect base in coronal sections of computed tomography
Time frame: Baseline and 12 months
Buccolingual width of the defect
Buccolingual width, in milimeters, assessed in axial sections of computed tomography
Time frame: Baseline and 12 months
Platelet-derived growth factor (PDGF)-BB
Quantification in pg/mL using a multiplex assay with Milliplex plates (Millipore)
Time frame: Baseline and 12 months
Vascular endothelial growth factor (VEGF)
Quantification in pg/mL using a multiplex assay with Milliplex plates (Millipore)
Time frame: Baseline and 12 months
Bone morphogenetic protein (BMP)-2
Quantification in pg/mL using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline and 12 months
Wound Healing Index (WHI).
A score from 1 to 3 will be assigned according to the following criteria: i) score 1 - uneventful healing, i.e., no gingival edema, erythema, suppuration, patient discomfort, or flap dehiscence; ii) score 2 - uneventful healing with slight gingival edema, erythema, patient discomfort, or flap dehiscence, but no suppuration; iii) score 3 - poor wound healing, with significant gingival edema, erythema, patient discomfort, flap dehiscence, or any suppuration.
Time frame: 1, 2 and 6 weeks
Visual Analogue Scale
Patients will complete a questionnaire using a 100 mm visual analogue scale (VAS) , where 0 means no pain/hardship and 100 means unbearable pain/hardship
Time frame: 2 weeks
Oral Health Impact Profile (OHIP-14) questionnaire
Oral health-related quality of life assessed using the 14-item Oral Health Impact Profile (OHIP-14) questionnaire. Each item is scored on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is calculated as the sum of all item responses, ranging from 0 to 56, with higher scores indicating worse oral health-related quality of life.
Time frame: Baseline, 6 and 12 months
Oral Health Related Quality of Life (OHRQoL-UK) questionnaire
Oral health-related quality of life assessed using the Oral Health-Related Quality of Life-UK (OHRQoL-UK) questionnaire. The instrument consists of 16 items covering physical, psychological, and social dimensions. Each item is scored on a 5-point scale ranging from 1 (very bad effect) to 5 (very good effect). The total score is calculated as the sum of all item responses, ranging from 16 to 80, with higher scores indicating better oral health-related quality of life.
Time frame: Baseline, 6 and 12 months
Plan to share: Yes — The data will be available from the investigator upon reasonable request.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for May 2028, 27 months after the start.
Of 484 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's planned 27 months is above that.
Counting every sponsor, half of 498 studies reached it within 15 months; a quarter within 8 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.